LV10287B - Peptide compounds - Google Patents
Peptide compoundsInfo
- Publication number
- LV10287B LV10287B LVP-93-458A LV930458A LV10287B LV 10287 B LV10287 B LV 10287B LV 930458 A LV930458 A LV 930458A LV 10287 B LV10287 B LV 10287B
- Authority
- LV
- Latvia
- Prior art keywords
- peptide compounds
- peptide
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C07K7/067—Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929211668A GB9211668D0 (en) | 1992-06-02 | 1992-06-02 | Peptide compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
LV10287A LV10287A (lv) | 1994-10-20 |
LV10287B true LV10287B (en) | 1995-04-20 |
Family
ID=10716403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-93-458A LV10287B (en) | 1992-06-02 | 1993-06-02 | Peptide compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US5629293A (lv) |
EP (1) | EP0643725A1 (lv) |
JP (1) | JPH08501067A (lv) |
CN (1) | CN1085912A (lv) |
AU (1) | AU4340493A (lv) |
EE (1) | EE03101B1 (lv) |
GB (1) | GB9211668D0 (lv) |
LT (1) | LT3615B (lv) |
LV (1) | LV10287B (lv) |
NO (1) | NO944670L (lv) |
TW (1) | TW329427B (lv) |
WO (1) | WO1993024524A1 (lv) |
ZA (1) | ZA933866B (lv) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425730D0 (en) * | 1994-12-20 | 1995-02-22 | Nycomed Pharma As | Compounds |
US6908899B2 (en) * | 2001-08-17 | 2005-06-21 | U.S. Dept. Of Veterans Affairs | Pro-inflammatory fibrinopeptide |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3778426A (en) * | 1970-12-16 | 1973-12-11 | Research Corp | Therapeutically useful polypeptides |
US4171299A (en) * | 1975-04-04 | 1979-10-16 | The Regents Of The University Of California | Polypeptide agents for blocking the human allergic response |
FI77875C (fi) | 1982-11-26 | 1989-05-10 | Nyegaard & Co As | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider. |
US4816449A (en) * | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
US4579840A (en) * | 1983-08-12 | 1986-04-01 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin Fc receptors |
FR2567524B1 (fr) * | 1984-07-10 | 1987-11-27 | Sanofi Sa | Procede de synthese de la somatocrinine en phase liquide et peptides intermediaires |
ZA846192B (en) * | 1984-08-09 | 1986-03-26 | Merck Patent Gmbh | Immunotherapeutic polypeptide agents |
GB8626539D0 (en) | 1986-11-06 | 1986-12-10 | Nycomed As | Peptide compounds |
GB8630721D0 (en) * | 1986-12-23 | 1987-02-04 | Unilever Plc | Cosmetic compositions |
GB8821785D0 (en) * | 1988-09-16 | 1988-10-19 | Nycomed As | Peptide compounds |
GB8905606D0 (en) * | 1989-03-11 | 1989-04-26 | Scras | Peptides |
ZW11290A1 (en) | 1989-07-14 | 1990-10-31 | Smithkline Beecham Corp | Hemoregulatory peptides |
HU206372B (en) * | 1990-09-03 | 1992-10-28 | Richter Gedeon Vegyeszet | Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same |
TW222280B (lv) * | 1991-11-26 | 1994-04-11 | Smithkline Beecham Corp |
-
1992
- 1992-06-02 GB GB929211668A patent/GB9211668D0/en active Pending
-
1993
- 1993-06-02 JP JP6500363A patent/JPH08501067A/ja active Pending
- 1993-06-02 CN CN93108406A patent/CN1085912A/zh active Pending
- 1993-06-02 ZA ZA933866A patent/ZA933866B/xx unknown
- 1993-06-02 EP EP93913277A patent/EP0643725A1/en not_active Withdrawn
- 1993-06-02 AU AU43404/93A patent/AU4340493A/en not_active Abandoned
- 1993-06-02 WO PCT/GB1993/001172 patent/WO1993024524A1/en not_active Application Discontinuation
- 1993-06-02 LT LTIP608A patent/LT3615B/lt not_active IP Right Cessation
- 1993-06-02 LV LVP-93-458A patent/LV10287B/xx unknown
- 1993-06-02 US US08/343,602 patent/US5629293A/en not_active Expired - Fee Related
- 1993-07-20 TW TW082105780A patent/TW329427B/zh active
-
1994
- 1994-11-16 EE EE9400181A patent/EE03101B1/xx unknown
- 1994-12-02 NO NO944670A patent/NO944670L/no unknown
Also Published As
Publication number | Publication date |
---|---|
LTIP608A (en) | 1995-01-31 |
AU4340493A (en) | 1993-12-30 |
LV10287A (lv) | 1994-10-20 |
JPH08501067A (ja) | 1996-02-06 |
US5629293A (en) | 1997-05-13 |
TW329427B (en) | 1998-04-11 |
NO944670D0 (no) | 1994-12-02 |
CN1085912A (zh) | 1994-04-27 |
WO1993024524A1 (en) | 1993-12-09 |
ZA933866B (en) | 1994-06-14 |
LT3615B (en) | 1995-12-27 |
GB9211668D0 (en) | 1992-07-15 |
NO944670L (no) | 1995-01-19 |
EE03101B1 (et) | 1998-06-15 |
EP0643725A1 (en) | 1995-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2269176B (en) | Peptides | |
AU4715493A (en) | Peptide compounds | |
AP9300508A0 (en) | Compounds | |
GB9200245D0 (en) | Compounds | |
GB9201755D0 (en) | Compounds | |
GB9200210D0 (en) | Compounds | |
GB9201694D0 (en) | Compounds | |
GB9201693D0 (en) | Compounds | |
GB9200209D0 (en) | Compounds | |
GB9226065D0 (en) | Peptides | |
GB9200566D0 (en) | Compounds | |
GB9201751D0 (en) | Compounds | |
GB9202792D0 (en) | Compounds | |
GB9201692D0 (en) | Compounds | |
GB9211677D0 (en) | Peptide compounds | |
GB9204274D0 (en) | Novel peptides | |
GB9211668D0 (en) | Peptide compounds | |
GB9324691D0 (en) | Peptide compounds | |
ZA933868B (en) | Peptide compounds | |
GB9211676D0 (en) | Peptide compounds | |
GB9211675D0 (en) | Peptide compounds | |
GB9226074D0 (en) | Peptide | |
GB9312867D0 (en) | Peptide compounds | |
GB9315987D0 (en) | Peptide compounds | |
GB9320875D0 (en) | Peptide compounds |